Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Tildrakizumab and the Development of a Concentration Response Curve of Tildrakizumab for Psoriasis Patients
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms BIOLOPTIM-TIL
- 17 Jan 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 05 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 16 Jan 2023 New trial record